logo
ResearchBunny Logo
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

Medicine and Health

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

K. Shitara, K. Muro, et al.

In the exciting Phase 3 PARADIGM trial involving 733 participants, researchers investigated how circulating tumor DNA (ctDNA) gene alterations impact treatment outcomes in RAS wild-type metastatic colorectal cancer. Discover whether first-line therapy using panitumumab could provide longer survival rates for patients without ctDNA alterations, as highlighted by the team of experts led by Kohei Shitara and Kei Muro.... show more
Citation Metrics
Citations
0
Influential Citations
0
Reference Count
0

Note: The citation metrics presented here have been sourced from Semantic Scholar and OpenAlex.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny